1. Almeida da Silva HC, Ferreira G, Rodrigues G, et al. Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil. Braz J Anesthesiol. 2019;69:152−9.

2. Rosenberg H, Sambuughin N, Riazi S, et al. Malignant Hyperthermia Susceptibility. 2003 Dec 19 [Updated 2020 Jan 16]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews
[Internet]. Seattle (WA): University of Washington, Seattle; 1993‒2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1146/.

3. Whitaker DK, Brattebo G, Smith AF, Staender SEA. The Helsinki Declaration on Patient Safety in Anaesthesiology: Putting words into practice. Best Pract Res Clin Anaesthesiol. 2011;25:277−90.

4. Brazilian Federal Council of Medicine (CFM). Resolution CFM 2174/2017. Brasília: Diario O
ficial da Uniao [DOU]; Feb 27, 2018. ~ Available from: https://sistemas.cfm.org.br/normas/visualizar/ resolucoes/BR/2017/2174.

5. Hopkins PM, Girard T, Dalay S, et al. Malignant Hyperthermia 2020: Guideline from the Association of Anaesthetists. Anaesthesia. 2021;76:655−64.

6. Ruffert H, Bastian B, Bendixen D, et al. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth. 2021;126:120−30.